| Literature DB >> 35721853 |
Segaran P Pillai1, Julia A Fruetel2, Kevin Anderson3, Rebecca Levinson2, Patricia Hernandez2, Brandon Heimer2, Stephen A Morse4.
Abstract
The Centers for Disease Control and Prevention (CDC) Select Agent Program establishes a list of biological agents and toxins that potentially threaten public health and safety, the procedures governing the possession, utilization, and transfer of those agents, and training requirements for entities working with them. Every 2 years the Program reviews the select agent list, utilizing subject matter expert (SME) assessments to rank the agents. In this study, we explore the applicability of multi-criteria decision analysis (MCDA) techniques and logic tree analysis to support the CDC Select Agent Program biennial review process, applying the approach broadly to include non-select agents to evaluate its generality. We conducted a literature search for over 70 pathogens against 15 criteria for assessing public health and bioterrorism risk and documented the findings for archiving. The most prominent data gaps were found for aerosol stability and human infectious dose by inhalation and ingestion routes. Technical review of published data and associated scoring recommendations by pathogen-specific SMEs was found to be critical for accuracy, particularly for pathogens with very few known cases, or where proxy data (e.g., from animal models or similar organisms) were used to address data gaps. Analysis of results obtained from a two-dimensional plot of weighted scores for difficulty of attack (i.e., exposure and production criteria) vs. consequences of an attack (i.e., consequence and mitigation criteria) provided greater fidelity for understanding agent placement compared to a 1-to-n ranking and was used to define a region in the upper right-hand quadrant for identifying pathogens for consideration as select agents. A sensitivity analysis varied the numerical weights attributed to various properties of the pathogens to identify potential quantitative (x and y) thresholds for classifying select agents. The results indicate while there is some clustering of agent scores to suggest thresholds, there are still pathogens that score close to any threshold, suggesting that thresholding "by eye" may not be sufficient. The sensitivity analysis indicates quantitative thresholds are plausible, and there is good agreement of the analytical results with select agent designations. A second analytical approach that applied the data using a logic tree format to rule out pathogens for consideration as select agents arrived at similar conclusions.Entities:
Keywords: biosecurity; logic tree analysis; multi-criteria; risk assesment; select agents and toxins
Year: 2022 PMID: 35721853 PMCID: PMC9204104 DOI: 10.3389/fbioe.2022.756586
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1Summary of the criteria and hierarchy captured in the MCDA framework and fact sheets.
HHS Select and non-select agents evaluated in this study.
| Bacteria |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fungi |
|
|
|
|
|
|
| Viruses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tier 1 select agent.
Overlap select agent.
Select agent.
Removed from the select agent list (CDC, HHS, 2012).
USDA select agent.
Criteria rank ordering by SMEs and assignment to one of three weighting groups (A, B or C).
| Criteria | Average ranking | SD | 5/4/6 Weighting group assignment | 3/3/9 Weighting group assignment |
|---|---|---|---|---|
| Case fatality rate | 2.8 | 3.7 | A | A |
| Degree of pathogenicity | 3.0 | 1.2 | ||
| Severity of illness | 3.2 | 3.6 | ||
| Rate of transmission | 4.7 | 2.0 | B | |
| Availability of MCM | 5.8 | 1.8 | ||
| Dissemination efficacy | 6.2 | 2.2 | B | |
| Ease of production | 8.5 | 2.7 | C | |
| Burden on health care system | 8.8 | 3.1 | ||
| Aerosol stability | 8.9 | 3.3 | ||
| Matrix stability | 10.3 | 3.5 | C | |
| Status of immunity | 10.4 | 3.0 | ||
| Long-term effects | 11.2 | 3.8 | ||
| Decon and restoration | 11.5 | 2.8 | ||
| Vulnerable populations | 11.9 | 3.1 | ||
| Ability to genetically manipulate | 12.0 | 2.5 |
Scoring basis used to generate four simulated test agents.
| Criteria | Not human pathogen | Not infectious by inhalation or ingestion | Low severity and low CFR | Not infectious |
|---|---|---|---|---|
| Ease of Production | ||||
| Production Skill | 10 | 10 | 10 | 10 |
| Growth Conditions | 10 | 10 | 10 | 10 |
| Growth Time | 10 | 10 | 10 | 10 |
| Production Yield | 10 | 10 | 10 | 10 |
| Storage Stability | 10 | 10 | 10 | 10 |
| Ability to Genetically Manipulate | 10 | 10 | 10 | 10 |
| Dissemination Efficacy | 10 | 10 | 10 | 10 |
| Aerosol Stability | 0 | 0 | 10 | 0 |
| Matrix Stability | 0 | 0 | 10 | 0 |
| Degree of Pathogenicity | ||||
| Route of Exposure | 0 | 2 | 10 | 2 |
| Infectious dose (ID50) | 0 | 0 | 10 | 0 |
| Severity of Illness | 0 | 10 | 4 | 4 |
| Status of Immunity | 0 | 10 | 10 | 10 |
| Case Fatality Rate | 0 | 10 | 0 | 0 |
| Rate of Transmission | 0 | 10 | 10 | 10 |
| Long-Term Effects | 0 | 10 | 10 | 10 |
| Availability of MCMs | 0 | 10 | 0 | 0 |
| Vulnerable Populations | 0 | 10 | 10 | 10 |
| Burden on Health Care | ||||
| Duration of MCM Treatment | 0 | 10 | 0 | 0 |
| Duration of Hospitalization | 0 | 10 | 0 | 0 |
| Decon and Restoration | ||||
| Environmental Stability | 10 | 10 | 10 | 10 |
| Post-Event Disease Persistence | 0 | 10 | 10 | 10 |
CFR, case fatality rate.
By inhalation of ingestion.
FIGURE 2Decision Support Framework for assignments of select and non-select agents.
Agents causing large numbers of asymptomatic or mild cases.
| Agent | Asymptomatic or mild (%) | Case fatality rate | References | |
|---|---|---|---|---|
| Reported | Value used for scoring | |||
|
| 90% asymptomatic | 5–6% | 0.5–0.6% |
|
| JEV | 99% asymptomatic | 20–30% | 0.2–0.3% |
|
| WNV | >99% mild-moderate | 10% | 0.1% |
|
| YFV | 50–85% asymptomatic, 15–25% of symptomatic become severe | 20–50% | 0.4–6% |
|
| Dengue virus | 8–13% hospitalized | <1% | <1% |
|
|
| 75% asymptomatic, 20% mild to moderate | 1.3% | 1.3% |
|
| LCMV | 33% asymptomatic | <1% | <1% |
|
|
| 60% asymptomatic or mild | 0.1% | 0.1% |
|
|
| ||||
|
| “Most” asymptomatic or mild | 4–8% | 4–8% |
|
| TBEV | 70–95% asymptomatic | 20–60% (Far Eastern); 6–8% (Siberian) | 20–60% (Far Eastern); 6–8% (Siberian) |
|
| RVFV | 91–99% asymptomatic or mild | 11–45% | <1% |
|
| Omsk virus | 50–70% mild-moderate | 0.5–10%; 0.4–2.5% | 0.5–10%; 0.4–2.5% |
|
| Lassa virus | 80% mild | 16.5–28% | 16.5–28% |
|
| EEEV | 95% mild | 33% | 33% |
|
|
| ||||
|
| 64% mild | 0.5% | 0.5% |
|
FIGURE 3Two-dimensional plots of unweighted (A), 5/4/6 grouping (B) and 3/3/9 grouping (C) normalized scoring results.
FIGURE 4Two-dimensional plot of normalized median scores with error bars (5th and 95th percentiles) for (A) 5/4/6 grouping results and (B) 3/3/9 grouping results.
Percentage of scenarios in the sensitivity analysis where the agent score was within the select agent region as defined by thresholds x ≥ 0.36 and y ≥ 0.56.
| Agent | 5/4/6 Grouping | 3/3/9 Grouping |
|---|---|---|
| 1918 Spanish Influenza | 100 | 67.2 |
|
| 0 | 0 |
|
| 100 | 100 |
|
| 0 | 0 |
|
| 9.6 | 0.4 |
|
| 100 | 100 |
|
| 0 | 0 |
|
| 100 | 100 |
|
| 0 | 0 |
|
| 0 | 0 |
|
| 0 | 0 |
| Ebola | 100 | 100 |
| EEEV | 100 | 66.2 |
|
| 89.3 | 97.2 |
| Hendra | 94.2 | 64.8 |
| Junin | 100 | 93.2 |
| KFDV | 100 | 93.2 |
| Lassa | 100 | 100 |
| Lujo | 100 | 84.3 |
| Machupo | 100 | 100 |
| Marburg | 100 | 100 |
| MERS | 0 | 0 |
| Monkeypox (Congo Basin) | 94.2 | 94 |
| RVFV | 69.7 | 93.2 |
| Sabia | 100 | 79.4 |
| SARS | 59.6 | 6.9 |
|
| 100 | 100 |
| VEEV (1AB and 1C) | 0 | 0 |
|
| 100 | 100 |
|
| 0 | 0 |
|
| 0 | 0 |
| Chikungunya | 0 | 0 |
| Dengue | 0 | 0 |
| Ebola (Reston & Bombali) | 0 | 0 |
| Flexal virus | 0 | 0 |
|
| 0 | 0 |
| H2N2 | 0 | 0 |
| Hantavirus (Andes) | 0 | 0 |
| Hantavirus (hi path HFRS) | 0 | 0 |
| Hantavirus (low path HFRS) | 0 | 0 |
| Hantavirus (Sin Nombre) | 0 | 0 |
| Herpes B virus | 0 | 0 |
| HIV | 0 | 0 |
| HPAI | 0 | 67.0 |
| HTLV | 0 | 0 |
| JEV | 0 | 0 |
|
| 0 | 0 |
| Madariga virus | 0 | 0 |
| Monkeypox WA | 0 | 0 |
|
| 0 | 0 |
| Polio virus | 0 | 0 |
|
| 0 | 1.5 |
| SFV | 0 | 0 |
| SIV | 0 | 0 |
| TBEV CE | 0 | 0.1 |
| TSE | 0 | 0 |
|
| 0 | 0 |
| VEEV (1D and 1E) | 0 | 0 |
| VSV | 0 | 0 |
| WNV | 0 | 0 |
| WWAV | 0 | 0 |
| YFV | 0 | 0 |
| Zika | 0 | 0 |